

Stockholm March 14, 2023

Neogap and Simsen Diagnostics enter collaboration to improve personalised cancer diagnostics



The biotechnology company Neogap and the cancer diagnostics company Simsen Diagnostics have initiated a collaboration aimed at improving personalised cancer diagnostics by examining circulating tumor DNA in the blood of patients participating in Neogap's phase I/II clinical trial. The goal is to develop more precise and effective diagnostic tools for cancer.

Neogap Therapeutics has previously announced its plans to initiate a phase I/II clinical trial of its personalised cell therapy for the treatment of patients with disseminated colorectal cancer.

Neogap's pTTL (personalized Trained Tumour Lymphocytes) cell therapy is an immunotherapy designed to treat solid tumors by training the immune system to recognize and attack cancer cells using specific altered proteins, so-called neoantigens.

Neogap has commissioned Simsen Diagnostics to measure the level of circulating tumor DNA (ctDNA) in the blood of patients participating in Neogap's upcoming immunotherapy trial. These measurements will be taken at several points during the treatment and will be used to evaluate

Stockholm March 14, 2023

the therapy's effect by comparing the development and survival of tumour cells over time. Neogap's proprietary PIOR® software will be used to analyse the data collected during the trial.

The collaboration opens up opportunities for developing innovative solutions for clinical diagnostics by leveraging each other's expertise and technologies. Neogap's development of a specific PIOR® module for ctDNA analysis is of interest to Simsen Diagnostics, which plans to offer services for clinical diagnostics in the future.

"Our technology PIOR® is a safe and regulated system for bioinformatic analysis of sequencing data that is also user-friendly. This provides the advantage of securely handling patient data while having the potential for multiple future applications in diagnostics and precision medicine. The collaboration with Simsen is an important step in expanding the PIOR® technology towards future commercialization and out-licensing of PIOR®, which is very exciting for us," says Samuel Svensson, CEO of Neogap Therapeutics.

"We are excited about the collaboration with Neogap Therapeutics, which allows us to offer our technology for ctDNA analysis to a significant player in the development of personalised cancer immunotherapy. The collaboration also gives us a chance to further develop our technology. By using a quality-assured system for data analysis, we can streamline our analysis and handle more data in less time. This collaboration accelerates our opportunities to become a company that can offer clinical diagnostics. We are confident that the collaboration will positively impact our ability to provide innovative solutions, " says Gustav Johansson, CEO of Simsen Diagnostics.

About Neogap's cell therapy

Neogap's pTTL cell therapy is an immunotherapy that treats solid tumors by training the immune system to recognize and attack cancer cells using specific altered proteins, so-called neoantigens. A neoantigen develops only in the tumour after a genetic mutation and can therefore be identified as foreign by the body's immune system. Neogap uses two technologies to create a personalised treatment for each patient: PIOR® and EpiTCer®. PIOR® selects the most suitable neoantigens for each patient, while EpiTCer® multiplies T cells that recognize the selected neoantigens and attack the cancer, leaving healthy tissue untouched. This minimizes the risk of side effects from the treatment.

For more information, please contact:

Samuel Svensson, CEO

Phone: +46 733 54 21 94

Email: samuel.svensson@neogap.se

About Neogap Therapeutics

Neogap Therapeutics is a Swedish biotechnology company focused on developing personalised

Stockholm March 14, 2023

cancer immunotherapy using the patient's own cells. The therapy is based on the company's two technologies PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at the Center for Molecular Medicine at the Karolinska Institute in Stockholm. To learn more about Neogap and its cutting-edge research, please visit the company's website at neogap.se and follow Neogap on [LinkedIn](#).

About Simsen Diagnostics

Simsen Diagnostics develops ultra-sensitive and user-friendly technologies for reading DNA sequences. The company currently serves customers in the pharmaceutical industry by providing a service for measuring cancer DNA in blood samples for clinical studies. The technology has a broad range of applications beyond the field of cancer. The company is based in the Sahlgrenska Science Park in Gothenburg and was founded on innovations from Anders Ståhlberg's research group at the Sahlgrenska Academy. For more information, please visit Simsen Diagnostics' website at www.simsendiagnosics.com.

For more information, please contact:

Gustav Johansson, CEO

Phone: +46 760 22 50 42

Email: gustav@simsendiagnosics.com